Drug Profile
Pegfilgrastim biosimilar - Eurofarma
Alternative Names: Peg-filgrastim biosimilar - Eurofarma; Recombinant pegfilgrastim - EurofarmaLatest Information Update: 25 Nov 2021
Price :
$50
*
At a glance
- Originator Eurofarma
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for phase-I development in Neutropenia(In volunteers) in Brazil (SC, Injection)
- 14 Sep 2017 Eurofarma Laboratorios withdraws a phase III trial in Breast cancer due to strategic changes regarding product development (NCT02768714)
- 01 Nov 2016 Eurofarma Laboratorios completes a phase I trial in Neutropenia (In volunteers) (NCT02589301)